The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Comparing haploidentical donors with mismatched unrelated donors in secondary AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, discusses the comparison of haploidentical donors with mismatched unrelated donors in secondary acute myeloid leukemia (AML). Prof. Nagler notes that haploidentical donors and mismatched unrelated donors with post-transplant cyclophosphamide (PTCy) show no difference in terms of outcome, and that a sibling donor is still the preferred option. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I presented an oral presentation this morning in which we compared haploidentical donors to mismatched unrelated donors for secondary AML. So for secondary AML, we have shown in a series of papers that haploidentical transplant may overcome the poor prognosis of secondary AML, can rescue about 60% of the patients in CR1 and about 30% of the patients with relapsed/refractory disease. And there was no difference if you use haplo and PTCy between de novo AML and secondary AML...
I presented an oral presentation this morning in which we compared haploidentical donors to mismatched unrelated donors for secondary AML. So for secondary AML, we have shown in a series of papers that haploidentical transplant may overcome the poor prognosis of secondary AML, can rescue about 60% of the patients in CR1 and about 30% of the patients with relapsed/refractory disease. And there was no difference if you use haplo and PTCy between de novo AML and secondary AML. And in the paper that I presented today, we compared haploidentical donors to mismatched unrelated donors with PTCy. And again, there was no difference. So the best donor in our hands, this is a paper that is in press in the American Journal of Hematology, is a sibling donor. But then if you have a haploidentical donor or mismatched unrelated donor, both can be an alternative if no sibling donor for secondary AML.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
